IGF1R and neoplasm: This is illustrated by linsitinib (1), a dual IGF1R/IR kinase inhibitor with IC50 values of 35 nM and 75 nM respectively.88In vivo analysis determined that linsitinib showed a dose-dependent effect on tumour growth inhibition.88 However, linsitinib did not progress past phase 3 clinical trials for metastatic cancer due to lack of efficacy.